Abstract: Objective To evaluate the efficacy and safety of 2% liranaftate cream in the treatment of tinea cruris,tinea corporis and tinea pedis.Methods A randomized,double blind,controlled study was performed in three centers.A total of 288 patients were enrolled into this study,and equally divided into 2 groups to receive 2% liranaftate cream (test group) and 1% bifonazole cream (control group) respectively. In every group,there were 72 patients with tinea cruris or tinea corporis and 72 patients with tinea pedis. Patients were instructed to apply the medications once a day.The patients with tinea cruris or tinea corporis were treated for 2 weeks and followed up every week;those with tinea pedis applied the drug for 4 weeks and were evaluated every 2 weeks.All patients were given a further consultation at 2 weeks after the end of treatment.Results A patient withdrew from the test group with tinea corporis or tinea cruris.At the end of treatment,the clinical cure rate and response rate in the test group amounted to 59.2% and 94.4% respectively for tinea corporis or tinea cruris,41.7% and 81.9% respectively for tinea pedis.Two weeks after the treatment ended,the clinical cure rate and response rate in the test group was 67.6% and 94.4% respectively for tinea corporis or tinea cruris,54.2% and 81.9% respectively for tinea pedis.The mycological clearance rates were 97.18% for tinea corporis or tinea cruris and 90.28% for tinea pedis in the per protocol set of test group at 2 weeks after the end of treatment,No significant difference (P>0.05) was noted in the above results between the test and control groups,Adverse reactions mainly included flare and pain at the site of application,occuring in 2.78% of patients with tinea corporis or tinea cruris in the test group.Conclusion Our study demonstrates that 2% liranaftate cream has a satisfactory effect on the treatment oftinea corporis,tinea cruris and tinea pedis.

Key words: Tinea, Randomized controlled trials, Liranaftate